Skip to main content
Article
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study
The Lancet (2018)
  • Robert Landewé, Department Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands
  • Joachim Sieper, Charité
  • Philip Mease, University of Washington
  • Robert D. Inman, Toronto Western Hospital
  • Robert G. Lambert, University of Alberta
  • Atulya Deodhar, Oregon Health & Science University
  • Helena Marzo-Ortega, National Institute for Health Research
  • Marina Magrey, Case Western Reserve University
  • Uta Kiltz, Rheumazentrum Ruhrgebiet, Herne, Germany
  • Xin Wang, AbbVie, North Chicago, IL, USA
  • Mei Li, AbbVie, North Chicago, IL, USA
  • Sheng Zhong, AbbVie, North Chicago, IL, USA
  • Nael M. Mostafa, AbbVie, North Chicago, IL, USA
  • Apinya Lertratanakul, AbbVie, North Chicago, IL, USA
  • Aileen L. Pangan, AbbVie, North Chicago, IL, USA
  • Jaclyn K. Anderson, AbbVie, North Chicago, IL, USA
Publication Date
July 1, 2018
DOI
10.1016/S0140-6736(18)31362-X
Citation Information
Robert Landewé, Joachim Sieper, Philip Mease, Robert D. Inman, et al.. "Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study" The Lancet Vol. 392 Iss. 10142 (2018) p. 134 - 144
Available at: http://works.bepress.com/philip-mease/358/